Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


La Jolla Pharmaceutical Co.

Latest From Vanderbilt Center for Neuroscience Drug Discovery

Deals Of The Week: Academic Drug-Discovery Group’s Work Catching Industry’s Notice

As academic labs fill gaps in discovery work once performed by biopharma companies, Roche is confident that a U.S. consortium of academic drug-discovery units will lead to broader partnerships between industry and academia and within the academy itself. Plus, MedImmune acquires ADC specialist Spirogen and other deals from the past week.

BioPharmaceutical United States

Academic Drug-Discovery Units Team Up To Share Knowledge, Facilitate Partnering

Founded in 2012, the Academic Drug Discovery Consortium intends to serve as a clearinghouse for both academia and industry on research underway at U.S. and international drug research programs. It won’t undertake tech transfer work itself, but the ADDC hopes to make it easier for academics and biopharma to work together.

BioPharmaceutical United States

Deals of the Week Watches Parkinson’s In Prime Time

Biogen Idec strikes a neurodegenerative research deal with Amicus Therapeutics and another antisense deal with Isis. Elsewhere, Merck and AstraZeneca team up in ovarian cancer, Roche obtains rights to two cancer immunotherapies from Inovio, and GSK sells a pair of beloved drinks to a Japanese beverage company.

BioPharmaceutical Consumer

Schizophrenia Dominates Psychiatric Drug Deal-Making Since 2008

Of 34 deals in the psychiatric disorder space since 2008, none have been mergers and acquisitions, but two-thirds of such transactions have involved licensing of compounds before regulatory approval. The major deals in the space have been a multi-compound collaboration between Otsuka and Lundbeck and the failed tie-up between AstraZeneca and Targacept.

BioPharmaceutical North America
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Hepatic (Liver)
  • Metabolic Disorders
  • Renal System
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • La Jolla Pharmaceutical Co.
  • Senior Management
  • George F Tidmarsh, MD, PhD, Pres. & CEO
    Dennis Mulroy, CFO
    James M Rolke, CSO
    Lakmir S Chawla, MD, CMO
    Jennifer A Carver, MBA, COO
  • Contact Info
  • La Jolla Pharmaceutical Co.
    Phone: (858) 207-4264
    10182 Telesis Ct., 6th Fl.
    San Diego, CA 92121